Schatz Nobel Izard P.C. Files Proposed Supplemental Class Action Complaint Against...

Schatz Nobel Izard P.C. Files Proposed Supplemental Class Action Complaint
Against Merck & Co., Inc. for Violations of the Employee Retirement Income
Security Act -- MRK

HARTFORD, Conn., April 17, 2008 (PRIME NEWSWIRE) -- The law firm of Schatz Nobel
Izard P.C., Chair of the Lead Counsel Committee in the Merck & Co, Inc. "ERISA"
Litigation, announces that Plaintiffs have filed a Proposed Supplemental Class
Action Complaint against Merck & Co., Inc. ("Merck") (NYSE:MRK) in the United
States District Court for the District of New Jersey. The action is on behalf of
participants in the Merck & Co., Inc. Employee Savings & Security Plan (the
"Salaried Plan"), the Merck & Co., Inc. Employee Stock Purchase & Savings Plan
(the "Hourly Plan"), the Merck Puerto Rico Employee Savings & Security Plan (the
"Puerto Rico Plan") and the Merck-Medco Managed Care, LLC 401(k) Savings Plan
(the "Medco Plan") (collectively the "Plans"), for violations of the Employee
Retirement Income Security Act ("ERISA").

The Proposed Supplemental Complaint has been amended to include additional ERISA
breach of fiduciary duty claims against Defendants arising from improprieties
relating to Vytorin, Merck's prescription anti-cholesterol drug. It is alleged,
inter alia, that Defendants negligently failed to disclose material information
about the effects of Vytorin necessary for participants to make informed
decisions concerning their investments in the Merck Common Stock Fund (the
"Fund"). The Proposed Complaint alleges that while Merck was publicly touting
Vytorin as a superior cholesterol treatment, it actively hid clinical study
results negating such claims. Merck knew or should have known that Vytorin, a
combination of the anti-cholesterol drugs simvastatin and Zetia, was no more
effective than simvastatin alone, which is available in a substantially cheaper
generic form. When the truth was revealed, the Plans and Plan participants
suffered massive losses as Merck's stock price and the price of the Fund
decreased substantially.

To view a copy of the Proposed Supplemental Complaint or for more information
about this case, class action cases in general, and your rights, please contact
Schatz Nobel Izard P.C. toll-free at (800) 797-5499, or by e-mail at
firm@snilaw.com, or visit our website: www.snilaw.com.

-0-
CONTACT: Schatz Nobel Izard P.C.
Wayne T. Boulton or Nancy A. Kulesa
(800) 797-5499
firm@snilaw.com
www.snilaw.com